Cargando…

Cost-effectiveness of intermediate or long-acting insulin versus Exenatide in type 2 diabetes mellitus patients not optimally controlled on dual oral diabetes medications

OBJECTIVE: To better understand exenatide’s role in the treatment of type 2 diabetes, this analysis assessed its cost-effectiveness in comparison to an intermediate (NPH) and long-acting insulin (glargine). Exenatide is a recently approved medication for the treatment of type 2 diabetes for use in a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Edwards, Krystal L., Irons, Brian K., Xu, Tom
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Centro de Investigaciones y Publicaciones Farmaceuticas 2006
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4156845/ https://www.ncbi.nlm.nih.gov/pubmed/25214899

Ejemplares similares

Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study
por: Davies, M J, et al.
Publicado: (2009)

Exenatide Use in the Management of Type 2 Diabetes Mellitus
por: Kyriacou, Angelos, et al.
Publicado: (2010)

Evaluation of the cost effectiveness of exenatide versus insulin glargine in patients with sub-optimally controlled Type 2 diabetes in the United Kingdom
por: Woehl, Anette, et al.
Publicado: (2008)

Exenatide versus Insulin Lispro Added to Basal Insulin in a Subgroup of Korean Patients with Type 2 Diabetes Mellitus
por: Yoon, Kun-Ho, et al.
Publicado: (2017)

Two cases of type 2 diabetes mellitus in elderly patients successfully treated with monthly exenatide long‐acting release
por: Takenaka, Kenchi, et al.
Publicado: (2019)

Long-acting preparations of exenatide
por: Cai, Yunpeng, et al.
Publicado: (2013)

Efficacy and safety of exenatide once‐weekly vs exenatide twice‐daily in Asian patients with type 2 diabetes mellitus
por: Ji, Linong, et al.
Publicado: (2013)

Cost-Effectiveness Analysis of Exenatide versus GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus
por: Capel, Margarita, et al.
Publicado: (2019)

Study of Postprandial Lipaemia in Type 2 Diabetes Mellitus: Exenatide versus Liraglutide
por: Voukali, Maria, et al.
Publicado: (2014)

Determining Predictors of Early Response to Exenatide in Patients with Type 2 Diabetes Mellitus
por: Khan, Muhammad, et al.
Publicado: (2015)

Effects of exenatide on postprandial vascular endothelial dysfunction in type 2 diabetes mellitus
por: Torimoto, Keiichi, et al.
Publicado: (2015)

Cost-effectiveness of the add-on exenatide to conventional treatment in patients with Parkinson’s disease when considering the coexisting effects of diabetes mellitus
por: Chen, Hsuan-Chih, et al.
Publicado: (2022)

Long-Term Effectiveness and Cost-Effectiveness of Metformin Combined with Liraglutide or Exenatide for Type 2 Diabetes Mellitus Based on the CORE Diabetes Model Study
por: Zhang, Xuesong, et al.
Publicado: (2016)

Evolution of Exenatide as a Diabetes Therapeutic
por: Bhavsar, Sunil, et al.
Publicado: (2013)

Acute Metabolic Effects of Exenatide in Patients With Type 1 Diabetes With and Without Residual Insulin to Oral and Intravenous Glucose Challenges
por: Ghazi, Tara, et al.
Publicado: (2014)

The Cost-effectiveness of Dulaglutide 1.5mg versus Exenatide QW for the Treatment of Patients with Type 2 Diabetes Mellitus in France
por: Basson, Mickael, et al.
Publicado: (2017)

Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus
por: Seewoodhary, Jason, et al.
Publicado: (2010)

Clinical experience with exenatide in obese North Indian patients with type 2 diabetes mellitus
por: Bawa, Tarunika, et al.
Publicado: (2013)

Hypoglycemia Abrogates the Vascular Endothelial Protective Effect of Exenatide in Type 2 Diabetes Mellitus
por: Torimoto, Keiichi, et al.
Publicado: (2019)

Exenatide Treatment for 6 Months Improves Insulin Sensitivity in Adults With Type 1 Diabetes
por: Sarkar, Gayatri, et al.
Publicado: (2014)

A real‐world, observational study of weekly exenatide added to basal insulin in patients with type 2 diabetes mellitus (NCT02895672)
por: Stryker, Matthew D., et al.
Publicado: (2017)

The effects of exenatide and insulin glargine treatments on bone turnover markers and bone mineral density in postmenopausal patients with type 2 diabetes mellitus
por: Akyay, Ozlem Zeynep, et al.
Publicado: (2023)

Safety, effectiveness, and cost effectiveness of long acting versus intermediate acting insulin for patients with type 1 diabetes: systematic review and network meta-analysis
por: Tricco, Andrea C, et al.
Publicado: (2014)

Safety, effectiveness, and cost of long-acting versus intermediate-acting insulin for type 1 diabetes: Protocol for a systematic review and network meta-analysis
por: Tricco, Andrea C, et al.
Publicado: (2013)

Effects of Ultra-Long-Acting Insulin Compared to Long-Acting Insulin on Diabetic Ketoacidosis Incidence in Type 1 Diabetes Mellitus Patients
por: Alsofiani, Wafa A, et al.
Publicado: (2022)

The vascular function effects of adding exenatide or meal insulin to basal insulin therapy in early type 2 diabetes
por: Retnakaran, Ravi, et al.
Publicado: (2023)

Safety of exenatide once weekly for 52 weeks in Japanese patients with type 2 diabetes mellitus
por: Onishi, Yukiko, et al.
Publicado: (2012)

Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes
por: Secnik Boye, Kristina, et al.
Publicado: (2006)

An ultra‐long‐acting recombinant insulin for the treatment of diabetes mellitus in cats
por: Gilor, Chen, et al.
Publicado: (2021)

Ultra‐long‐acting recombinant insulin for the treatment of diabetes mellitus in dogs
por: Hulsebosch, Sean E., et al.
Publicado: (2022)

PEGylated exenatide injection (PB-119) improves beta-cell function and insulin resistance in treatment-naïve type 2 diabetes mellitus patients
por: Liu, Xu, et al.
Publicado: (2023)

Resource use and costs of exenatide bid or insulin in clinical practice: the European CHOICE study
por: Kiiskinen, Urpo, et al.
Publicado: (2013)

The Short-Term Cost-Effectiveness of Once-Daily Liraglutide Versus Once-Weekly Exenatide for the Treatment of Type 2 Diabetes Mellitus in the United States
por: Wang, Bruce, et al.
Publicado: (2015)

Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled Type 2 diabetes on oral antidiabetic drugs in Greece
por: Tzanetakos, Charalampos, et al.
Publicado: (2014)

Exenatide Improves Bone Quality in a Murine Model of Genetically Inherited Type 2 Diabetes Mellitus
por: Pereira, Marie, et al.
Publicado: (2017)

Exenatide treatment causes suppression of serum fasting ghrelin levels in patients with type 2 diabetes mellitus
por: Guclu, Metin, et al.
Publicado: (2017)

Effects of PPARD gene variants on the therapeutic responses to exenatide in chinese patients with type 2 diabetes mellitus
por: Song, Jinfang, et al.
Publicado: (2022)

Combined antidiabetic benefits of exenatide and dapagliflozin in diabetic mice
por: Tatarkiewicz, K, et al.
Publicado: (2014)

Once-Weekly Exenatide in Youth With Type 2 Diabetes
por: Tamborlane, William V., et al.
Publicado: (2022)

Patients with Type 2 Diabetes Initiating Exenatide Twice Daily or Insulin in Clinical Practice: CHOICE Study
por: Matthaei, Stephan, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_a7kfim5fvfn5lm3agrr34t3o34